HEALTH● LOWAug 14 · Aug 14, 2026, 3:27 PM
Acurx outlines 20-patient PATHFINDER start in Q4 as FDA stays open to a single Phase III ASPIRE for ibezapolstat
Seeking Alpha Tech
Acurx plans to start its 20-patient PATHFINDER trial in Q4, with the FDA remaining open to a single Phase III ASPIRE trial for ibezapolstat. This indicates progress in the development and regulatory pathway for the drug.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH14m agoAfrica faces 'complex' Ebola outbreak after spread to Nigeria: WHOFrance 24 [en]HEALTH17m agoEbola: Swiss government says Nigeria’s patient likely contracted virus in UgandaPremium TimesHEALTHBREAKING44m agoFG intensifies response to confirmed Ebola case in FCTVanguard NigeriaHEALTH1h agoWHO warns Africa faces ‘complex’ Ebola outbreak as virus reaches NigeriaSouth China Morning Post